Quick Takeaways
- Roivant Sciences Ltd. filed SCHEDULE 13D/A for Immunovant, Inc. Common Stock, par value $0.0001 per share (IMVT).
- Disclosed ownership: 57%.
- Date of event: 13 Jan 2025.
Roivant Sciences Ltd. - 13 Jan 2025 SCHEDULE 13D/A Report for Immunovant, Inc. Common Stock, par value $0.0001 per share (IMVT)
- Filing Manager
- Roivant Sciences Ltd.
- Reporting Manager
- Roivant Sciences Ltd.
- Symbol
- IMVT
- Shares outstanding
- 169,877,576 shares
- Disclosed Ownership
- 96,660,341 shares
- Ownership
- 57%
- Form type
- SCHEDULE 13D/A
- Filing time
- 15 Jan 2025, 16:30:46 UTC
- Date of event
- 13 Jan 2025
- Next filing
- 21 Apr 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Roivant Sciences Ltd. disclosed 57% ownership in Immunovant, Inc. Common Stock, par value $0.0001 per share (IMVT) on 13 Jan 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 15 Jan 2025, 16:30.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Roivant Sciences Ltd. | 57% | 96,660,341 | 96,660,341 | 0 | /s/ Keyur Parekh | Keyur Parekh, Authorized Signatory | 0001635088 |